

Table of Contents

CONTENTS	PAGE NO.
Chapter 1	1
Introduction and Review of Literature on Redox Metabolism of <i>Leishmania</i> Parasites	1
Abstract	1
1.1 Introduction to Leishmaniasis	2
1.2 Pathogenesis and Establishment of <i>Leishmania</i> Infection	3
1.2.1 Modulation of Immune Signalling	5
1.2.2 Inhibition of Phagolysosome Maturation	7
1.2.3 Neutralization of Reactive Oxygen Species	7
1.3 Redox Biology in Pathogenesis	8
1.3.1 Redox Homeostasis	8
1.3.2 Antioxidant Defence System	11
1.3.2.1 Enzymatic Antioxidants	11
1.3.2.2 Non-Enzymatic Antioxidants	12
1.4 Unique Redox Metabolism of the <i>Leishmania</i> Parasites	13
1.4.1 Trypanothione-Based Redox Control	15
1.4.1.1 Key Enzymes and Therapeutic Targets in Redox Biology of <i>Leishmania</i> parasites	19
(A) Trypanothione Synthetase	19
(B) Trypanothione Reductase	20
(C) γ -Glutamylcysteine Synthetase	22
(D) Glutathione Synthetase	23
1.4.2 Immunological Aspects of Redox Biology	24

1.4.3	Role of Redox Metabolism in Drug Resistance	26
1.5	Current Anti-Leishmanial Drugs and Their Limitations	30
1.5.1	Antimoniate	30
1.5.2	Amphotericin B	30
1.5.3	Liposomal Amphotericin B	31
1.5.4	Paromomycin	32
1.5.5	Miltefosine	32
1.5.6	Sitamaquine	33
1.5.7	Pentamidine	34
1.6	Antiparasitic Efficacy of Molecules Targeting Redox Metabolism	34
1.7	Rationale for Developing New Chemotherapeutics	38
1.8	Discussion	39
Chapter 2		43
Validation of Glutathione Synthetase as a Therapeutic Target Through Gene Knockout Using CRISPR-Cas9		
	Abstract	43
2.1	Introduction	44
2.2	Materials and methods	47
2.2.1	Parasite Culture and Chemicals	47
2.2.2	Generation of Cas9 and T7 RNAP expressing <i>Leishmania donovani</i>	50
2.2.3	Generation of for Glutathione synthetase-heterozygous (-/+) and nullmutants (-/-) <i>Leishmania donovani</i>	51
2.2.4	Confirmation of glutathione synthetase-heterozygous disruption (-/+) and null mutant <i>Leishmania donovani</i> (-/-)	55

2.2.5	Generation of GS-tagged mNeoGreen Expressing <i>L. donovani</i>	55
2.2.6	Growth Analysis	57
2.2.7	Fluorescence Microscopy	57
2.2.8	<i>In vitro</i> Infectivity Test	57
2.3	Results	58
2.3.1	Expression of Cas9 and T7 RNA polymerase Does Not Affect the Growth of <i>Leishmania donovani</i>	58
2.3.2	The Cas9/T7RNA pol system successfully tagged mNeon Green to endogenous GS	59
2.3.3	Glutathione Synthetase Gene in <i>L. donovani</i> is Present in Multiple Genomic Loci	60
2.3.4	Disruption of a Single Locus of the Glutathione Synthetase Gene Reduces the Promastigote Growth in <i>L. donovani</i>	60
2.3.5	Disruption of a Single Locus of the Glutathione Synthetase Gene Impairs the Infectivity of <i>L. donovani</i> in Macrophage Cells	64
2.4	Discussion	64
Chapter 3		69
	Structure-Based Drug Design Targeting Glutathione Synthetase of <i>Leishmania donovani</i>	69
	Abstract	69
3.1	Introduction	70
3.2	Materials and Methods	72
3.2.1	Target preparation	71
3.2.2	Ligand library preparation	73
3.2.3	Molecular docking	73
3.2.4	Molecular dynamics simulation studies	74

3.2.5	MMPBSA free energy analysis	75
3.3	Results	75
3.3.1	Homology modeling of glutathione synthetase	75
3.3.2	Interactions of the compounds with <i>Leishmania donovani</i> glutathione synthetase (LdGS) and human glutathione synthetase (hGS)	77
3.3.3	Dynamics of protein-ligand complexes	81
3.3.4	Binding free energy calculation	83
3.4	Discussion	84
 Chapter 4		89
Experimental Evaluation of Inhibitors Against Glutathione Synthetase and Their Impact on Parasite Survival		89
	Abstract	89
4.1	Introduction	90
4.2	Materials and Methods	94
4.2.1	Materials	94
4.2.2	Parasites and cell line	94
4.2.3	Anti-Leishmanial activity	95
4.2.4	Cloning and expression of recombinant LdGS gene	96
4.2.5	Relative activity and inhibition studies of LdGS	97
4.2.6	Cytotoxicity assay	97
4.3	Results	98
4.3.1	Compounds inhibit <i>L. donovani</i> promastigotes at varying Concentrations	98
4.3.2	Valrubicin and ciclesonide exhibit moderate cytotoxicity to host cells	100
4.3.3	Cloning and expression of recombinant <i>L. donovani</i> Glutathione Synthetase (LdGS)	103

4.3.4	Activity of the recombinant LdGS enzyme was inhibited by valrubicin and ciclesonide	103
4.4	Discussion	105
Chapter 5		109
Mechanism of Cell Death and Biochemical Alterations in <i>Leishmania donovani</i>		109
	Abstract	109
5.1	Introduction	110
5.2	Materials and Methods	111
5.2.1	Materials	111
5.2.2	Scanning Electron Microscopy (SEM) Analysis	111
5.2.3	Reactive oxygen species analysis	112
5.2.4	Flow cytometric analysis of cell cycle	112
5.2.5	DNA laddering assay	113
5.2.6	Annexin V/PI dual staining for apoptosis/ necrotic study	113
5.3	Results	114
5.3.1	Drugs alter the cellular morphology of <i>L. donovani</i> promastigotes and induce intracellular ROS in the parasites	114
5.3.2	Intracellular ROS of <i>L. donovani</i> promastigotes in a dose-dependent manner	114
5.3.3	Drugs arrest the cell cycle of the parasite at G0/G1 phase	115
5.3.4	Drug-induced caspase activation leading to the DNA laddering	117
5.4.5	Annexin V/PI staining indicates apoptosis-like events	120
5.4	Discussion	122

Chapter 6	127
CONCLUSION & FUTURE SCOPE	127
REFERENCES	133
APPENDIX A	169
LIST OF PUBLICATIONS FROM THESIS WORK	169
LIST OF PUBLICATIONS FROM COLLABORATION	169
APPENDIX B	171
CONFERENCES & WORKSHOPS	171